AIHealthcare

Tome Biosciences is a private biotechnology company developing programmable genomic integration (PGI) technologies for genomic medicines. Its platform is designed to insert DNA sequences—including entire genes—at specified genomic locations, potentially without introducing double-strand DNA breaks. The company has described both integrase-mediated PGI for larger DNA sequences and ligase-mediated PGI for smaller sequences. Its stated therapeutic focus has included in vivo gene therapies for monogenic liver diseases and ex vivo cell therapies for autoimmune diseases, with reported preclinical programs involving phenylketonuria and renal autoimmune disease. Tome emerged from stealth in December 2023 after raising $213 million across Series A and Series B financings. Public reporting in August 2024 stated that the company had reduced operations, was exploring strategic options, and planned to eliminate 131 positions; no later reliable operating-status update is established by the available sources. Although it operates at the intersection of advanced biotechnology and computationally enabled genomic medicine, the available sources do not substantiate a distinct AI healthcare product or AI-first business model.